{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tuberculosis/background-information/definition/","result":{"pageContext":{"chapter":{"id":"c26e051a-e3f8-57b8-95af-985e9e93a3aa","slug":"definition","fullItemName":"Definition","depth":2,"htmlHeader":"<!-- begin field 25037f82-1634-4029-a20a-a6d6891f7ef8 --><h2>What is it?</h2><!-- end field 25037f82-1634-4029-a20a-a6d6891f7ef8 -->","summary":"","htmlStringContent":"<!-- begin item e4577fab-c0bd-4b11-b9c4-65755f56ac1c --><!-- begin field c1480008-cdf8-4acb-8f5c-3d3c3f661423 --><ul><li><strong>Tuberculosis (TB) is an infection caused by bacteria of the <em>Mycobacterium tuberculosis </em>complex, </strong>predominantly <em>Mycobacterium tuberculosis </em>and more rarely <em>Mycobacterium bovis</em> or <em>africanum</em>. Almost all cases in the UK are infected by inhaling the bacterium in respiratory droplets that are released when a person with infectious active pulmonary or laryngeal TB coughs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Dheda, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">PHE, 2016</a>].<ul><li><strong>Active disease</strong> describes where there is evidence of symptomatic or progressive disease of the lung and/or other organs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Behr, 2018</a>].<ul><li>Active pulmonary TB is the most common presentation, accounting for 54.4% of all cases in the UK in 2017 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">PHE, 2018a</a>].</li><li>Active extrapulmonary TB presents with symptoms specific to the site involved, such as the central nervous system (typically the meninges), peripheral lymph nodes, bones and joints, pericardium, skin, gastrointestinal and genitourinary systems [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>].</li></ul></li><li><strong>Latent disease </strong>is defined as a state of persistent immune response to stimulation by <em>Mycobacterium tuberculosis</em> antigens, with no evidence of clinically active TB (the person is asymptomatic and not infectious) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">WHO, 2018a</a>].<ul><li>There is a 5–10% lifetime risk of progression to active (symptomatic) disease if, for example, the person becomes immunocompromised or has intercurrent illness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Hartman-Adams, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Dheda, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>].</li><li>Multiple longitudinal epidemiological studies indicate that the majority of TB disease occurs soon after initial infection, with disease rarely occurring more than two years after infection. In countries with a low TB burden where ongoing transmission is minimal, such as the UK, the interval between initial infection and active disease may be longer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Behr, 2018</a>].</li></ul></li><li><strong>Multidrug-resistant TB </strong>refers to a strain of TB that is resistant to two first-line drugs (isoniazid and rifampicin), with or without any other drug resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Millard, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>].</li><li><strong>Extensively drug-resistant TB</strong> refers to multidrug-resistant TB with additional resistance to any fluoroquinolone and also any one of the three specialist second-line injectable agents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Millard, 2015</a>].</li></ul></li></ul><!-- end field c1480008-cdf8-4acb-8f5c-3d3c3f661423 --><!-- end item e4577fab-c0bd-4b11-b9c4-65755f56ac1c -->","topic":{"id":"c8d06469-2b39-5daa-bda8-b076b7204860","topicId":"c1897d19-8ea9-40e5-84a7-c45a80747a3e","topicName":"Tuberculosis","slug":"tuberculosis","lastRevised":"Last revised in January 2019","chapters":[{"id":"7216c242-e6e9-5726-9bad-d4bbd4071072","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"aa25f749-53e8-5ff7-a3be-ddfd9f824295","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9c40ce5c-b940-5a6e-a414-cb379ae5f2c1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5b948ae0-2789-5df7-b344-42eb6ae4054d","slug":"changes","fullItemName":"Changes"},{"id":"706989f4-45e1-583c-bcbc-d08833e25634","slug":"update","fullItemName":"Update"}]},{"id":"5edbfe3e-e825-5d79-a1d2-fa1b3b258467","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2e115c8b-8ca5-587b-bf34-83ddeeae2383","slug":"goals","fullItemName":"Goals"},{"id":"dbbfc2a1-e777-55e9-b654-44db5bf1efb4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bdce292e-6c5f-53df-a014-fc8432efa249","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1f5efb77-1619-5cf3-be88-86fd03247324","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6f93c9e3-2eb5-5d68-bbc0-99b7ea53b835","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a028a0db-e900-5a0f-88ba-f333bcd824c9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"24cda0d7-3e0d-58d5-9229-0a15e99013c4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c26e051a-e3f8-57b8-95af-985e9e93a3aa","slug":"definition","fullItemName":"Definition"},{"id":"2deaf55e-4677-569a-a2e0-a8748b44829f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f2d695cb-4d0e-5513-a7f3-01df45726347","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"dc328fb0-65a2-5d6a-94fe-0bfa42962928","slug":"complications","fullItemName":"Complications"},{"id":"72382f51-4bac-5de9-9caf-c6f16082070d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7e56c88f-1492-52ab-9f0b-cfc6b986db85","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b5294e44-2490-5ba7-8d81-0085ae3114a7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b90838b4-5d6d-57e8-aabd-afaad5a60e3f","slug":"investigations","fullItemName":"Investigations"},{"id":"8d7ee3e2-c863-574f-a042-172b8d909e84","slug":"screening","fullItemName":"Screening"},{"id":"a6c65c83-026b-50f1-b32d-5d28e8e7ae46","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"880c8c31-e325-5d4b-b4de-6ac05a1a9f94","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ab22745-718a-5096-a75f-2e6c874d6267","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"fd726cd9-2566-5903-9e38-d7333b140c5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ac0b667-89b4-5934-98e1-938fd35e537f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3834823-1bb2-52a0-92c5-cb04316db808","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b2e2271f-aaf8-57a5-aba4-42de8a475bc5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e611555b-70b5-5ea6-8e53-5220621e1603","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fdb64832-ab19-58f6-978e-d73fe8657b7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"200b04d2-7d10-5430-abe3-3802b135aea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74113d46-a800-5f0b-9d3d-096dc4137936","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"24cda0d7-3e0d-58d5-9229-0a15e99013c4","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}